Gerresheimer AG, one of the leading worldwide suppliers to the pharma and healthcare industry, has acquired the Brazilian company Védat to strengthen its pharmaceutical plastic packaging business in South America. Védat is a major Brazilian manufacturer of pharmaceutical plastic packaging products, especially plastic closures.
“Expanding in emerging markets is a key component of our growth strategy. The acquisition of Védat, a technology leader and very profitable company in Brazil, is significantly strengthening our position in the South American pharmaceutical primary packaging market. It perfectly fits our strategy of doubling our sales in the emerging markets from EUR 100 million to EUR 200 million by 2013,” commented Uwe Röhrhoff, CEO of Gerresheimer AG.
Védat has an excellent positioning in the South American market for pharmaceutical plastic packaging. Its product portfolio comprises plastic closures, PET bottles and other plastic containers and the majority of its customers are in the South American pharmaceutical industry. Gerresheimer already manufactures pharmaceutical plastic packaging and medical plastic systems for the South American market at three plants in Brazil and one plant in Argentina.
“Now that we have the combination of bottles and closures, we can provide a fully comprehensive range of products and services to our South American pharmaceutical customers on a one stop shop basis. Védat will help us to take an important step forward as a full-service partner for pharmaceutical plastic packaging in South America,” added Uwe Röhrhoff.
Védat, located in Sao Paolo, Brazil, generated annual sales of BRL 106 million (approximately EUR 45 million) in 2010 and it employs approximately 450 people.
Please visit www.vedat.com.br for further information about Védat.
Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop solutions which set standards and have role model status in their respective market sectors.
Our Group realizes revenues of around one billion Euros and has 10,000 employees at 45 locations in Europe, North and South America and Asia. We use first-rate technologies, convincing innovations and targeted investments to systematically consolidate our strong market position.